Amyloid-β and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model.
暂无分享,去创建一个
W. Klein | William L Klein | Claudine L Bitel | Chinnaswamy Kasinathan | Rajesh H Kaswala | Peter H Frederikse | C. Kasinathan | P. Frederikse | Claudine L. Bitel
[1] M. Vitek,et al. Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[2] W. Thies,et al. 2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.
[3] W. Klein,et al. Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.
[4] T. Holzman,et al. β/A4‐evoked degeneration of differentiated SH‐SY5Y human neuroblastoma cells , 1994 .
[5] S. M. de la Monte,et al. Insulin resistance and Alzheimer's disease. , 2009, BMB reports.
[6] D. Selkoe,et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.
[7] T. Bliss,et al. Long‐lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path , 1973, The Journal of physiology.
[8] Suzanne Craft,et al. Insulin resistance syndrome and Alzheimer's disease: Age- and obesity-related effects on memory, amyloid, and inflammation , 2005, Neurobiology of Aging.
[9] C. Glabe. Conformation-dependent antibodies target diseases of protein misfolding. , 2004, Trends in biochemical sciences.
[10] M. Rowan,et al. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. , 2005, Biochemical Society transactions.
[11] Christian Hölscher,et al. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. , 2011, Biochemical Society transactions.
[12] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[13] S. Gandy,et al. The role of cerebral amyloid β accumulation in common forms of Alzheimer disease , 2005 .
[14] Yicheng Feng,et al. Increased expression and local accumulation of the Prion Protein, Alzheimer Aβ peptides, superoxide dismutase 1, and Nitric oxide synthases 1 & 2 in muscle in a rabbit model of diabetes , 2010, BMC Physiology.
[15] Transgenic Models of Alzheimer’s Disease , 2001 .
[16] K. Zahs,et al. ‘Too much good news’ – are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? , 2010, Trends in Neurosciences.
[17] W. Klein,et al. Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers , 2009, Proceedings of the National Academy of Sciences.
[18] T. Montine,et al. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .
[19] H. Vinters,et al. β-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin , 2009, The Journal of Neuroscience.
[20] R. Munday,et al. The relationship between the physicochemical properties and the biological effects of alloxan and several N-alkyl substituted alloxan derivatives. , 1993, The Journal of endocrinology.
[21] W. Engel,et al. Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers , 2010, Acta Neuropathologica.
[22] Ann Marie Schmidt,et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.
[23] A. Zmijewska,et al. Tau Is Hyperphosphorylated at Multiple Sites in Mouse Brain In Vivo After Streptozotocin-Induced Insulin Deficiency , 2006, Diabetes.
[24] A. Schmidt,et al. The RAGE axis in early diabetic retinopathy. , 2005, Investigative ophthalmology & visual science.
[25] Alan W. Stitt,et al. AGEs, RAGE, and Diabetic Retinopathy , 2011, Current diabetes reports.
[26] Wei⁃qin Zhao,et al. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. , 2009, Biochimica et biophysica acta.
[27] S. Kanba,et al. Insulin resistance is associated with the pathology of Alzheimer disease , 2010, Neurology.
[28] R. Martins,et al. Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein‐E Genotype , 2000, Annals of the New York Academy of Sciences.
[29] A. Chobanian,et al. Effect of dietary cholesterol and alloxan-diabetes on tissue cholesterol and apolipoprotein E mRNA levels in the rabbit. , 1991, Journal of lipid research.
[30] John Hardy,et al. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. , 2005, The American journal of pathology.
[31] D. Selkoe,et al. Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway* , 2007, Journal of Biological Chemistry.
[32] Colin L. Masters,et al. Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer’s disease , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.
[33] H. Mori,et al. Absence of synaptophysin near cortical neurons containing oligomer Aβ in Alzheimer's disease brain , 2006, Journal of neuroscience research.
[34] S. Little,et al. Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. , 1991, Brain research. Molecular brain research.
[35] S. Feinstein,et al. Amyloid β-Mediated Cell Death of Cultured Hippocampal Neurons Reveals Extensive Tau Fragmentation without Increased Full-length Tau Phosphorylation* , 2011, The Journal of Biological Chemistry.
[36] B. Hyman,et al. Transgenic models of Alzheimer’s disease: Learning from animals , 2005, NeuroRX.
[37] D. Munoz,et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. , 2012, The Journal of clinical investigation.
[38] M. Vestling,et al. Amyloid-β Oligomer Specificity Mediated by the IgM Isotype – Implications for a Specific Protective Mechanism Exerted by Endogenous Auto-Antibodies , 2010, PloS one.
[39] L. Frölich,et al. Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. , 2009, Journal of Alzheimer's disease : JAD.
[40] J. Götz,et al. Experimental Diabetes Mellitus Exacerbates Tau Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2009, PloS one.
[41] Christian Hölscher,et al. The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease , 2011, The Journal of Neuroscience.
[42] M. Mattson,et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.
[43] C. Heizmann,et al. Site-Specific Blockade of RAGE-Vd Prevents Amyloid-β Oligomer Neurotoxicity , 2008, The Journal of Neuroscience.
[44] P. Worley,et al. Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development , 2012, Neuropsychopharmacology.
[45] W. Klein,et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[46] K. Imahori,et al. Amyloid β peptide induces cytoplasmic accumulation of amyloid protein precursor via tau protein kinase I/glycogen synthase kinase-3β in rat hippocampal neurons , 1995, Neuroscience Letters.
[47] E. Bigio,et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.
[48] Xiaohua Douglas Zhang,et al. Inhibition of Calcineurin-mediated Endocytosis and α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors Prevents Amyloid β Oligomer-induced Synaptic Disruption , 2009, The Journal of Biological Chemistry.
[49] T Szkudelski,et al. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. , 2001, Physiological research.
[50] E. Masliah,et al. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice , 2010, Experimental Neurology.
[51] K. Ono,et al. Low‐n oligomers as therapeutic targets of Alzheimer’s disease , 2011, Journal of neurochemistry.
[52] R. Martins,et al. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. , 1985, The EMBO journal.
[53] C. Carlsson,et al. Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.
[54] K. Imahori,et al. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[55] D. Selkoe,et al. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.
[56] W. Klein,et al. Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.
[57] C. Finch,et al. Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[58] Ying Liu,et al. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes , 2011, The Journal of pathology.
[59] Gianluigi Forloni,et al. APP Transgenic Mice: Their Use and Limitations , 2011, NeuroMolecular Medicine.
[60] J. Disterhoft,et al. Connections of the caudal anterior cingulate cortex in rabbit: Neural circuitry participating in the acquisition of trace eyeblink conditioning , 2007, Neuroscience.
[61] M. S. Alhamdani,et al. Hypoglycemic and antioxidant effect of oleuropein in alloxan-diabetic rabbits. , 2006, Life sciences.
[62] R. Raffa,et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? , 2011, British journal of clinical pharmacology.
[63] Zina Kroner,et al. The relationship between Alzheimer's disease and diabetes: Type 3 diabetes? , 2009, Alternative medicine review : a journal of clinical therapeutic.
[64] Virginia M. Y. Lee,et al. Molecular features of hypothalamic plaques in Alzheimer's disease. , 1991, The American journal of pathology.
[65] K. Hsu,et al. Insulin rescues amyloid β-induced impairment of hippocampal long-term potentiation , 2009, Neurobiology of Aging.
[66] W. Klein,et al. Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ* , 2009, The Journal of Biological Chemistry.
[67] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[68] J. McArdle,et al. Convergence of pre- and postsynaptic influences on glucosensing neurons in the ventromedial hypothalamic nucleus. , 2001, Diabetes.
[69] J. Schnabel. Amyloid: Little proteins, big clues , 2011, Nature.
[70] K. Ohno-Matsui. Parallel findings in age-related macular degeneration and Alzheimer’s disease , 2011, Progress in Retinal and Eye Research.
[71] V. Hachinski,et al. Changing perspectives regarding late-life dementia , 2009, Nature Reviews Neurology.
[72] Ryuichi Morishita,et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes , 2010, Proceedings of the National Academy of Sciences.
[73] S. Gandy,et al. Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease. , 2010, The Mount Sinai journal of medicine, New York.
[74] C. Glabe,et al. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction , 2009, Neurobiology of Disease.
[75] G. Cole,et al. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer’s Disease , 2007, Experimental Gerontology.
[76] R. Boado. Amplification of blood–brain barrier GLUT1 glucose transporter gene expression by brain-derived peptides , 2001, Neuroscience Research.
[77] K. Maiese,et al. Mechanistic insights into diabetes mellitus and oxidative stress. , 2007, Current medicinal chemistry.
[78] Rie Teraoka,et al. A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo , 2010, The Journal of Neuroscience.
[79] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[80] M. Goedert,et al. Glycogen synthase kinase-3β phosphorylates tau protein at multiple sites in intact cells , 1995, Neuroscience Letters.
[81] W. Klein,et al. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease , 2011, Neurobiology of Learning and Memory.
[82] Dong-Hou Kim,et al. Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells , 2010, Neurobiology of Disease.
[83] K. Duff,et al. Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? , 2004, Briefings in functional genomics & proteomics.
[84] G. Johnson,et al. Hyperosmotic stress‐induced apoptosis and tau phosphorylation in human neuroblastoma cells , 2001, Journal of neuroscience research.
[85] Fatmire Berisha,et al. Retinal abnormalities in early Alzheimer's disease. , 2007, Investigative ophthalmology & visual science.
[86] Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. , 1993 .
[87] W. Klein,et al. Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.
[88] J. Luchsinger,et al. Insulin Dysfunction Induces In Vivo Tau Hyperphosphorylation through Distinct Mechanisms , 2007, The Journal of Neuroscience.